NEW YORK (GenomeWeb News) - Investment bank Piper Jaffray today upgraded the stock of Genomic Health while downgrading its rating on Becton Dickinson.

It upgraded Genomic Health from "neutral" to "overweight."

The Redwood City, Calif.-based pharmacogenomic test maker yesterday announced the worldwide launch of its Oncotype Dx colon cancer test. The 12-gene expression test has been developed for assessing risk of disease recurrence in patients that have stage II colon cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.